Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.86
PODD's Cash-to-Debt is ranked lower than
57% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.24 vs. PODD: 0.86 )
Ranked among companies with meaningful Cash-to-Debt only.
PODD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.1 Max: N/A
Current: 0.86
Equity-to-Asset 0.14
PODD's Equity-to-Asset is ranked lower than
93% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. PODD: 0.14 )
Ranked among companies with meaningful Equity-to-Asset only.
PODD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.37  Med: 0.26 Max: 0.73
Current: 0.14
-2.37
0.73
Piotroski F-Score: 5
Altman Z-Score: 3.48
Beneish M-Score: -2.60
WACC vs ROIC
17.32%
-32.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -7.66
PODD's Operating Margin % is ranked lower than
67% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.97 vs. PODD: -7.66 )
Ranked among companies with meaningful Operating Margin % only.
PODD' s Operating Margin % Range Over the Past 10 Years
Min: -945.81  Med: -33.87 Max: -4.26
Current: -7.66
-945.81
-4.26
Net Margin % -11.55
PODD's Net Margin % is ranked lower than
69% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.14 vs. PODD: -11.55 )
Ranked among companies with meaningful Net Margin % only.
PODD' s Net Margin % Range Over the Past 10 Years
Min: -981.44  Med: -46.59 Max: -11.55
Current: -11.55
-981.44
-11.55
ROE % -113.13
PODD's ROE % is ranked lower than
93% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.92 vs. PODD: -113.13 )
Ranked among companies with meaningful ROE % only.
PODD' s ROE % Range Over the Past 10 Years
Min: -178.71  Med: -92.23 Max: -49.42
Current: -113.13
-178.71
-49.42
ROA % -15.30
PODD's ROA % is ranked lower than
72% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. PODD: -15.30 )
Ranked among companies with meaningful ROA % only.
PODD' s ROA % Range Over the Past 10 Years
Min: -97.25  Med: -31.5 Max: -15.3
Current: -15.3
-97.25
-15.3
ROC (Joel Greenblatt) % -58.58
PODD's ROC (Joel Greenblatt) % is ranked lower than
76% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.87 vs. PODD: -58.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PODD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -310.53  Med: -166.07 Max: -58.58
Current: -58.58
-310.53
-58.58
3-Year Revenue Growth Rate 9.00
PODD's 3-Year Revenue Growth Rate is ranked higher than
70% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. PODD: 9.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PODD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 16.8 Max: 99.7
Current: 9
0
99.7
3-Year EBITDA Growth Rate 15.10
PODD's 3-Year EBITDA Growth Rate is ranked higher than
75% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. PODD: 15.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PODD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.4  Med: -34 Max: 15.9
Current: 15.1
-64.4
15.9
3-Year EPS without NRI Growth Rate 6.10
PODD's 3-Year EPS without NRI Growth Rate is ranked higher than
51% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. PODD: 6.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PODD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -71  Med: -21.7 Max: 31.2
Current: 6.1
-71
31.2
GuruFocus has detected 4 Warning Signs with Insulet Corp $PODD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PODD's 10-Y Financials

Financials (Next Earnings Date: 2017-02-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PODD Guru Trades in Q1 2016

Jim Simons 222,400 sh (+172.55%)
Mariko Gordon 1,483,179 sh (+12.66%)
Ken Fisher 16,963 sh (unchged)
Steven Cohen Sold Out
PRIMECAP Management 5,194,369 sh (-0.03%)
Pioneer Investments 255,521 sh (-11.02%)
» More
Q2 2016

PODD Guru Trades in Q2 2016

Jim Simons 620,892 sh (+179.18%)
Ken Fisher 16,963 sh (unchged)
Mariko Gordon Sold Out
PRIMECAP Management 5,189,472 sh (-0.09%)
Pioneer Investments 32,665 sh (-87.22%)
» More
Q3 2016

PODD Guru Trades in Q3 2016

Ron Baron 5,032 sh (New)
Ken Fisher 16,963 sh (unchged)
Pioneer Investments 32,665 sh (unchged)
PRIMECAP Management 5,179,572 sh (-0.19%)
Jim Simons 470,400 sh (-24.24%)
» More
Q4 2016

PODD Guru Trades in Q4 2016

Pioneer Investments 32,665 sh (unchged)
Ken Fisher 16,963 sh (unchged)
Ron Baron Sold Out
PRIMECAP Management 5,179,272 sh (-0.01%)
Jim Simons 127,000 sh (-73.00%)
» More
» Details

Insider Trades

Latest Guru Trades with PODD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:ANSLY, NAS:ICUI, NYSE:HAE, NAS:NXTM, OTCPK:TOPCF, NYSE:CMD, OTCPK:GNGBY, NAS:MMSI, NYSE:HRC, NAS:ATRI, NAS:LMNX, NAS:OSUR, NAS:ANGO, OTCPK:NNCSF, NAS:ATRC, NAS:ELGX, NAS:MLAB, AMEX:CRHM, NAS:STAA, NAS:LMAT » details
Traded in other countries:GOV.Germany,
Insulet Corp is a medical device company that develops, manufactures and markets OmniPod Insulin Management System, an insulin infusion system for people with insulin-dependent diabetes.

Insulet Corp is a Delaware corporation formed in July 2000. The Company is engaged in the development, manufacturing and sale of OmniPod Insulin Management System. The OmniPod System is a disposable tubeless OmniPod worn on the body for approximately three days at a time. OmniPod Insulin Management System consists of disposable tubeless OmniPod worn on the body for approximatley three days at a time. The OmniPod System features two devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. In October 2005 the Company began its commercial sale of OmniPod System in the United States. The Company sells OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through distribution partners. The OmniPod System is available in Europe through distribution partner, Ypsomed Distribution AG and in Canada through the distribution partner GlaxoSmithKline. The Company's sales and marketing effort is focused on generating demand and acceptance of the OmniPod System among diabetes practitioners, academic medical centers, clinics, insulin-dependent diabetes patients, third-party payors, government agencies, and third-party distributors. The marketing strategy is to build awareness for the benefits of the OmniPod System through education programs, social networking, patient demonstration programs, support materials, media advertisements and events at the national, regional and local levels. As of December 31, 2013, the Company had obtained 15 issued United States patents, and had 8 additional pending U.S. patent applications. It has registered the trademarks OMNIPOD, INSULET and the OMNIPOD design with the United States Patent and Trademark Office on the Principal Register. The OmniPod System competes with Medtronic MiniMed, Animas Corporation, Tandem Diabetes Care, Inc. and Roche Diagnostics, a division of F. Hoffmann-La Roche, Ltd.

Top Ranked Articles about Insulet Corp

Weekly CEO Buys Highlights Insiders purchase shares of Sohu.com, Insulet, PJT, SiteOne and CoreSite
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Insulet Insider Invests in Company CEO purchases 40,000 shares
Insulet Corp. (PODD) CEO and Chairman Patrick Sullivan (Insider Trades) acquired 40,000 shares of the company on Dec. 2. The price was $33.89 per share for a total transaction of $1,355,600. Read more...

Ratios

vs
industry
vs
history
PB Ratio 40.70
PODD's PB Ratio is ranked lower than
99% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.34 vs. PODD: 40.70 )
Ranked among companies with meaningful PB Ratio only.
PODD' s PB Ratio Range Over the Past 10 Years
Min: 3.13  Med: 15.9 Max: 1235
Current: 40.7
3.13
1235
PS Ratio 6.44
PODD's PS Ratio is ranked lower than
80% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. PODD: 6.44 )
Ranked among companies with meaningful PS Ratio only.
PODD' s PS Ratio Range Over the Past 10 Years
Min: 1.58  Med: 5.99 Max: 22.41
Current: 6.44
1.58
22.41
Current Ratio 6.67
PODD's Current Ratio is ranked higher than
89% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.27 vs. PODD: 6.67 )
Ranked among companies with meaningful Current Ratio only.
PODD' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 4.69 Max: 8.04
Current: 6.67
0.67
8.04
Quick Ratio 6.07
PODD's Quick Ratio is ranked higher than
91% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.59 vs. PODD: 6.07 )
Ranked among companies with meaningful Quick Ratio only.
PODD' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 4.3 Max: 7.56
Current: 6.07
0.56
7.56
Days Inventory 35.03
PODD's Days Inventory is ranked higher than
93% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. PODD: 35.03 )
Ranked among companies with meaningful Days Inventory only.
PODD' s Days Inventory Range Over the Past 10 Years
Min: 26.04  Med: 49.61 Max: 111.63
Current: 35.03
26.04
111.63
Days Sales Outstanding 34.52
PODD's Days Sales Outstanding is ranked higher than
90% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.72 vs. PODD: 34.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
PODD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.52  Med: 60.44 Max: 141.2
Current: 34.52
34.52
141.2
Days Payable 33.15
PODD's Days Payable is ranked lower than
75% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.25 vs. PODD: 33.15 )
Ranked among companies with meaningful Days Payable only.
PODD' s Days Payable Range Over the Past 10 Years
Min: 28.7  Med: 46.8 Max: 80.41
Current: 33.15
28.7
80.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.60
PODD's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. PODD: -5.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PODD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -354.5  Med: -18.6 Max: -0.9
Current: -5.6
-354.5
-0.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 107.37
PODD's Price-to-Tangible-Book is ranked lower than
98% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.49 vs. PODD: 107.37 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PODD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.41  Med: 21.19 Max: 1123
Current: 107.37
3.41
1123
Price-to-Median-PS-Value 1.08
PODD's Price-to-Median-PS-Value is ranked higher than
55% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. PODD: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PODD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1 Max: 2.86
Current: 1.08
0.27
2.86
Earnings Yield (Greenblatt) % -1.19
PODD's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. PODD: -1.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PODD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.1  Med: 0 Max: 0
Current: -1.19
-5.1
0

More Statistics

Revenue (TTM) (Mil) $407.5
EPS (TTM) $ -0.82
Beta2.08
Short Percentage of Float11.66%
52-Week Range $26.50 - 46.92
Shares Outstanding (Mil)57.43

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 364 422 489
EPS ($) -0.50 -0.13 -0.04
EPS without NRI ($) -0.50 -0.13 -0.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PODD

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlights Dec 12 2016 
Insulet Insider Invests in Company Dec 06 2016 
Mariko Gordon's Trades In Q1 2015 Jun 12 2015 
Weekly CEO Buys Highlight: NUVA, HK, BKFS, PODD, CLF Jun 02 2015 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 24,400 Shares Feb 18 2011 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 27,000 Shares Feb 15 2011 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) May 07 2010 
Insulet Corp. (PODD) COO Luis Malave sells 6,000 Shares Dec 23 2009 

More From Other Websites
Insulet reports 4Q loss Feb 27 2017
Insulet reports 4Q loss Feb 27 2017
INSULET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 27 2017
Insulet Reports Fourth Quarter and Full Year 2016 Financial Results Feb 27 2017
Q4 2016 Insulet Corp Earnings Release - After Market Close Feb 27 2017
Insulet Presents Strong Omnipod® Horizon™ Hybrid Closed-Loop Study Results at ATTD in Paris Feb 17 2017
Insulet Completes Acquisition of U.S. Manufacturing Facility in Acton, Massachusetts Feb 15 2017
Insulet Corporation to Present at Upcoming Investor Conferences Feb 13 2017
Insulet Corporation to Announce Fourth Quarter and Full Year 2016 Financial Results on February 27,... Jan 23 2017
DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage Jan 13 2017
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Insulet, Western Refining, PennyMac... Jan 11 2017
Insulet upgraded by Robert W. Baird Jan 06 2017
INSULET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 21 2016
INSULET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Dec 20 2016
Insulet Corporation to Present at Upcoming Investor Conference Dec 20 2016
Insulet Corporation to Present at Upcoming Investor Conference Dec 20 2016
ETFs with exposure to Insulet Corp. : December 16, 2016 Dec 16 2016
Insulet Corp. – Value Analysis (NASDAQ:PODD) : December 12, 2016 Dec 12 2016
Weekly CEO Buys Highlights Dec 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)